查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464919

树突细胞癌疫苗市场：依癌症类型、最终用途划分 - 2024-2030 年全球预测

Dendritic Cell Cancer Vaccine Market by Cancer Type (Breast Cancer, Liver Cancer, Lung Cancer), End-use (Hospitals, Research Institutes, Specialty Clinics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

树突细胞癌疫苗市场规模预计2023年为3.5006亿美元，2024年达到3.9259亿美元，预计2030年将达到8.2649亿美元，复合年增长率为13.05%。

树突细胞癌症疫苗利用树突细胞诱发针对癌症的免疫反应。树突细胞疫苗是免疫疗法的一种形式，旨在教导免疫系统更有效地识别和攻击癌细胞。树突细胞癌疫苗主要应用于多种癌症的治疗和管理，包括前列腺癌、黑色素瘤和白血病。公营和私营部门对研发活动的资金增加正在扩大对树突状细胞癌疫苗的需求。全球癌症负担日益增加，需要先进的治疗方法和树突细胞疫苗。树突状细胞疫苗的开发和生产相关的高成本阻碍了市场成长。针对个别癌症特征和免疫系统的疫苗开发的进步和功效的提高预计将为市场成长创造机会。扩大使用树突细胞疫苗与其他癌症治疗相结合以改善患者预后的研究活动预计将扩大市场范围。

主要市场统计
基准年[2023] 35006万美元
预测年份 [2024] 3.9259 亿美元
预测年份 [2030] 8.2649亿美元
复合年增长率（%） 13.05%

癌症类型：特异性针对癌细胞的前列腺癌树突状细胞癌疫苗增加了可能性

乳癌是世界上最常见的癌症之一，对创新治疗方案的需求很大。树突细胞疫苗因其提供标靶免疫疗法、降低復发率和提高长期存活率的潜力而受到关注。由于其侵袭性和肝臟在药物代谢中的作用，肝癌提出了独特的挑战。树突细胞疫苗因其能够特异性靶向癌细胞并刺激强大的免疫反应而无明显毒性而特别有价值。肺癌死亡率很高，需要创新的治疗方法。树突细胞疫苗为个别患者提供了一种非侵入性的选择，并有可能改变肺癌治疗的模式。卵巢癌通常在晚期才被诊断出来，因此创新的治疗方法非常重要。树突状细胞疫苗因其在诱导针对卵巢癌特异性肿瘤抗原的强烈免疫反应方面的作用而引人注目。胰臟癌的性质和不良预后增加了对树突状细胞疫苗等创新治疗方法的需求，这为透过个人化免疫疗法改善存活率带来了希望。前列腺癌是男性最常见的癌症之一，增加了对特异性针对癌细胞而不影响正常组织的治疗方法的需求。树突细胞疫苗是一个快速发展的领域，具有持久缓解和减少副作用的潜力。

最终用途：在综合护理设施医院增加树突状细胞癌疫苗的使用。

医院是树突细胞癌疫苗的重要最终使用部分，因为它们是包括癌症患者的诊断、治疗和追踪的综合护理设施。大型医院，尤其是肿瘤专科医院，将是管理这些疫苗的关键。医院的需求是由对综合医疗服务和针对肿瘤的多学科团队提供个人化护理的需求所推动的。研究机构对于树突状细胞癌疫苗的开发和进步至关重要。这些研究机构经常与生物技术公司合作，推动疫苗开发和临床试验的前沿。研究机构因其有能力进行深入研究、重要临床试验和开发下一代癌症疫苗而受到青睐。专科诊所为树突状细胞癌疫苗的接种提供了更集中和专业的环境，专门针对特定的癌症患者。这些诊所与研究机构和医院密切合作，确保患者接受最新的治疗，并提供适合每位患者的治疗方案。专科诊所以患者为中心，提供量身定制的治疗计划和后续护理。

区域洞察

在美洲，人们非常关注技术创新和癌症疫苗的开发。美洲持有多项与树突细胞癌疫苗相关的专利，凸显其在研发方面的主导地位。美国国立卫生美国(NIH) 等政府机构和私人企业的资助和投资十分活跃，并正在促进高级临床试验。欧盟在「地平线欧洲」等计画下促进成员国之间的重要研究措施和合作。这种合作促进了专利申请和创新治疗方法的引入。欧洲药品管理局 (EMA) 在核准和监管树突状细胞癌疫苗、确保其安全性和有效性方面发挥关键作用。在中东和非洲地区，人们对包括树突细胞疫苗在内的先进癌症治疗方法越来越感兴趣。亚太地区树突状细胞癌疫苗市场显示出巨大的成长潜力。由于政府对生物技术研究的大力支持、有利的监管政策和大量投资，包括中国和日本在内的国家处于领先地位。日本凭藉其先进的医疗保健系统和研究能力，不断为创新癌症治疗方法的发展做出贡献。

FPNV定位矩阵

FPNV定位矩阵对于评估树突状细胞癌疫苗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对树突状细胞癌疫苗市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估及资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行综合评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.树突细胞癌疫苗市场规模及预测为何？

2.在树突细胞癌疫苗市场预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.树突细胞癌疫苗市场的技术趋势和法规结构是什么？

4.树突状细胞癌疫苗市场主要厂商的市场占有率是多少？

5.进入树突状细胞癌疫苗市场的合适形式和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率增加
      • 免疫疗法和个人化医疗的持续进步
    • 抑制因素
      • 树突细胞疫苗技术开发成本高
    • 机会
      • 加大树突细胞生物学和疫苗技术领域的研发力度
      • 加速癌症治疗开发的支持性法规结构
    • 任务
      • 对树突细胞疫苗技术的好处认识不足
  • 市场区隔分析
    • 癌症类型：可特异性靶向癌细胞的前列腺癌树突状细胞癌疫苗的潜力不断增长
    • 最终用途：在医院综合护理设施中增加树突状细胞癌疫苗的使用
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章树突细胞癌疫苗市场：依癌症类型

  • 乳癌
  • 肝癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第七章树突细胞癌疫苗市场：依最终用途分类

  • 医院
  • 调查机构
  • 专科诊所

第八章美洲树突细胞癌疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区树突细胞癌疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲树突细胞癌疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • BioNTech 开始基于 mRNA 的个人化新抗原特异性免疫疗法的 2 期试验，扩大后期临床肿瘤学产品组合
  • 战略分析和建议

第十二章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-351BAD503B28

[194 Pages Report] The Dendritic Cell Cancer Vaccine Market size was estimated at USD 350.06 million in 2023 and expected to reach USD 392.59 million in 2024, at a CAGR 13.05% to reach USD 826.49 million by 2030.

The dendritic cell cancer vaccine utilizes dendritic cells to induce an immune response against cancer. Dendritic cell vaccines are a form of immunotherapy that aims to teach the immune system to recognize and attack cancer cells more effectively. Dendritic cell cancer vaccines find their primary application in the treatment and management of several cancers, such as prostate cancer, melanoma, and leukemia. Rising funding in research and development activities from both public and private sectors is expanding the need for dendritic cell cancer vaccines. The growing global cancer burden globally necessitates advanced therapies and dendritic cell vaccines. The high associated with the development and production of dendritic cell vaccines hamper the market growth. The growing development of vaccines tailored to the individual's cancer profile and immune system for enhanced effectiveness is expected to create opportunities for market growth. Expanding research activities that combine the use of dendritic cell vaccines with other cancer treatments to improve patient outcomes are expected to expand the scope of the market.

KEY MARKET STATISTICS
Base Year [2023] USD 350.06 million
Estimated Year [2024] USD 392.59 million
Forecast Year [2030] USD 826.49 million
CAGR (%) 13.05%

Cancer Type: Rising potential of dendritic cell cancer vaccine for prostate cancer that can specifically target cancer cells

With breast cancer being one of the most common cancers worldwide, there is a significant demand for innovative treatment options. Dendritic cell vaccines are sought after for their potential to offer targeted immunotherapy, reduce recurrence rates, and improve long-term survival. Liver cancer presents unique challenges due to its aggressive nature and the liver's role in drug metabolism. Dendritic cell vaccines are particularly valuable for their ability to specifically target cancer cells and stimulate a robust immune response without significant toxicity. Lung cancer's high mortality rate necessitates innovative treatment approaches. Dendritic cell vaccines offer a non-invasive option that can be tailored to individual patients, potentially transforming lung cancer treatment paradigms. Ovarian cancer is often diagnosed at a late stage, making innovative treatments critical. Dendritic cell vaccines are appealing due to their role in eliciting a strong immune response against tumor antigens specific to ovarian cancer. The nature and poor prognosis associated with pancreatic cancer heighten the need for innovative therapies, inclduing dendritic cell vaccines, which offer hope for improving survival rates through personalized immunotherapy. Prostate cancer is one of the most prevalent cancers in men, with a growing need for treatments that can specifically target cancer cells without affecting normal tissue. Dendritic cell vaccines represent a burgeoning field offering the potential for sustained remission and fewer side effects.

End-use: Rising usage of dendritic cell cancer vaccine across hospitals due to their comprehensive care facilities

Hospitals represent a crucial end-use segment for dendritic cell cancer vaccines due to their comprehensive care facilities, including diagnosis, treatment, and follow-up for cancer patients. Larger hospitals, particularly those with specialized oncology departments, are key to administering these vaccines. The need in hospitals is driven by the requirement for integrative healthcare services and multidisciplinary teams specializing in oncology to provide personalized medicine. Research institutes are pivotal in the development and advancement of dendritic cell cancer vaccines. These institutes often partner with biotechnological companies to push the frontiers of vaccine development and clinical trials. The preference for research institutes emanates from their capability to conduct in-depth studies, critical trials, and development of next-generation cancer vaccines. Specialty clinics offer a more focused and specialized setting for the administration of dendritic cell cancer vaccines, catering specifically to patients with certain types of cancers. These clinics provide personalized care, often collaborating closely with both research organizations and hospitals to ensure the latest treatments are available. Specialty clinics are favored for their patient-centric approach, offering tailored treatment plans and follow-up care.

Regional Insights

In the Americas, there is a strong emphasis on innovation and the development of cancer vaccines. The Americas holds numerous patents related to dendritic cell cancer vaccines, underscoring its leading position in research and development. Funding and investments from both governmental bodies, such as the National Institutes of Health (NIH) and private entities, are robust, facilitating advanced clinical trials. The EU promotes significant research initiatives and collaborations across member states under programs including, Horizon Europe. Such cooperation enhances patent filings and the introduction of innovative therapies. The European Medicines Agency (EMA) plays a crucial role in the approval and regulation of dendritic cell cancer vaccines, ensuring their safety and efficacy. The Middle East & Africa region exhibit growing interest in advanced cancer treatments, including dendritic cell vaccines. Asia-Pacific region demonstrates significant potential for growth in the dendritic cell cancer vaccine market. Countries including China and Japan are at the forefront, driven by strong governmental support for biotechnology research, favorable regulatory policies, and substantial investments. Japan, with its advanced healthcare system and research capabilities, continues to contribute to the development of innovative cancer treatments.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dendritic Cell Cancer Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dendritic Cell Cancer Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dendritic Cell Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include Aduro Biotech, APAC Biotech, Argos Therapeutics, Batavia Biosciences B.V., Creative Biolabs, Dendreon Pharmaceuticals, GSK PLC, ImmunoCellular Therapeutics, JW CreaGene, Northwest Biotherapeutics, Northwest Biotherapeutics, Inc., and Nouscom.

Market Segmentation & Coverage

This research report categorizes the Dendritic Cell Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Cancer Type
    • Breast Cancer
    • Liver Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
  • End-use
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dendritic Cell Cancer Vaccine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dendritic Cell Cancer Vaccine Market?

3. What are the technology trends and regulatory frameworks in the Dendritic Cell Cancer Vaccine Market?

4. What is the market share of the leading vendors in the Dendritic Cell Cancer Vaccine Market?

5. Which modes and strategic moves are suitable for entering the Dendritic Cell Cancer Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer cases worldwide
      • 5.1.1.2. Continuous advancements in immunotherapy and personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of dendritic cell vaccine technology
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research and development efforts in the field of dendritic cell biology and vaccine technology
      • 5.1.3.2. Supportive regulatory frameworks for accelerating the development of cancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness associated with benefits of dendritic cell vaccine technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cancer Type: Rising potential of dendritic cell cancer vaccine for prostate cancer that can specifically target cancer cells
    • 5.2.2. End-use: Rising usage of dendritic cell cancer vaccine across hospitals due to their comprehensive care facilities
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Dendritic Cell Cancer Vaccine Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Liver Cancer
  • 6.4. Lung Cancer
  • 6.5. Ovarian Cancer
  • 6.6. Pancreatic Cancer
  • 6.7. Prostate Cancer

7. Dendritic Cell Cancer Vaccine Market, by End-use

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Research Institutes
  • 7.4. Specialty Clinics

8. Americas Dendritic Cell Cancer Vaccine Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Dendritic Cell Cancer Vaccine Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Dendritic Cell Cancer Vaccine Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DENDRITIC CELL CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DENDRITIC CELL CANCER VACCINE MARKET DYNAMICS
  • FIGURE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DENDRITIC CELL CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LIVER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 39. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 42. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 43. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 46. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 47. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 50. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 51. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 56. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 70. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 71. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 74. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 75. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 78. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 79. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 82. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 83. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 86. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 90. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 91. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 98. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 99. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 102. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 103. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 110. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 117. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 120. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 121. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 128. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 129. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 132. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 133. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 140. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 141. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 144. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 152. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 153. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 156. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 157. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 160. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 161. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 164. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 165. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 172. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 177. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 184. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 188. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 189. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 200. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 201. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 202. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023